FORTE BIOSCIENCES INC (FBRX)
Health Care · Clinical-stage monoclonal antibody therapeutics for autoimmune diseases · NASDAQ
A clinical-stage biotech developing an anti-CD122 antibody (FB102) to modulate immune cells in autoimmune diseases, with promising early celiac disease data and trials underway in vitiligo and alopecia areata.
What FORTE BIOSCIENCES INC does
Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, a proprietary anti-CD122 monoclonal antibody intended to treat autoimmune and autoimmune-related disorders by antagonizing IL-2/IL-15 receptors that regulate NK cells and T cell subsets. The company is advancing FB102 through Phase 1b and Phase 2 trials in celiac disease, non-segmental vitiligo, and alopecia areata, with positive Phase 1b data in celiac disease showing significant reduction in intestinal intraepithelial lymphocyte counts and gluten challenge-induced symptoms.
Themes: monoclonal antibodies / immunotherapy, autoimmune diseases, celiac disease treatment, vitiligo treatment, alopecia areata treatment, NK cell regulation
Fundamentals
- Price$76.92 as of 2026-08-21 close
- Market cap$1.1B as of 2026-08-21
- 1-year return+592.3% 2025-08-21 close $11.11 → 2026-08-21 close $76.92
- P/En/a negative earnings
- Net margin-158775.0% as of 2026-08-24
- ROE-106.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-99.8% as of 2026-08-24
- Revenue CAGR (3y)-9.8% SEC XBRL
- Beta2.30 as of 2026-08-24
- Last reported earnings2026-05-14 SEC EDGAR Form 8-K (Item 2.02)
How FBRX compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How FORTE BIOSCIENCES INC looks technically
FORTE BIOSCIENCES INC (FBRX) is trading 146.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 27 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 82, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 84, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day high about 17 trading days ago. It is trading right at its highest price of the past year (its 52-week high). Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 146.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +146.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $49.18 | $49.18 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $31.16 | $31.16 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 22 calendar days ago — the swings before that are what the structure reading is measured on | 22 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 27 trading days ago — a "golden cross", a bullish long-term signal | 27 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 146.8% above | +146.8% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 82, with buyers in control | 82.1 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 84, in overbought territory (above 70) | 84.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($76.51 to $76.95) — its "stochastic" reading is 93 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. Read that with care: its whole 14-day range is only about 0.6% of the price, so being at one end of it is a smaller move than it sounds — a company pinned near an agreed takeover price does this. | 93.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $77.20 | $77.20 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.4% |
| Above the 52-week low | it is 660.8% above its 52-week low (its lowest price of the past year) | +660.8% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.4% |
| Since a 20-day breakout | it made a new 20-day high about 17 trading days ago | 17 sessions |
| Since a 55-day breakout | it made a new 55-day high about 17 trading days ago | 17 sessions |
| All-time high | its highest closing price on record is $6732.38 (set on 2017-05-08) | $6732.38 |
| Given back of the 52-week move | over the past year its closes ranged ($10.30 to $76.98), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $33.64 to $35.77. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.1% |
| From the all-time high | it is 98.9% below its all-time high | -98.9% |
| Nearest price level | it is trading 53.6% above a support level at $35.71 — a price it turned at twice since 2026-01-27, most recently on 2026-04-09. Since 2024-08-21 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -53.6% |
| All-time low | its lowest closing price on record is $4.11 (set on 2024-11-01) | $4.11 |
| Above the all-time low | it is 1771.5% above its all-time low | +1,772% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.56 between its high and its low — about 2.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.56 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $76.47 and $77.06 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $76.47 – $76.77 – $77.06 |
| Typical daily range (% of price) | its price moves about 2.0% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.0% |
| Stretch from the 200-day average | it is trading 29.4 daily ranges above its 200-day average price (146.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 29.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.96× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a bearish engulfing | 1 session ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.1% |
|---|---|---|
| Open gap | it gapped 39.5% above the previous close 19 sessions ago and has not traded back through the level it left behind at 54.78 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +39.5% |
| Gap filled | a 2.2% gap down opened on 2026-07-23 has been "filled" 21 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 21 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 49.3 percentage points (the stock gained 51.6% while the market gained 2.3%) | +49.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 246.5 percentage points (the stock gained 249.6% while the market gained 3.1%) | +246.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 153.8 percentage points (the stock gained 164.9% while the market gained 11.1%) | +153.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 571.9 percentage points (the stock gained 592.3% while the market gained 20.5%) | +571.9% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 140% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.4% of the share price, which is taken to mean a barrier that gives way easily. | +139.8% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 40% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $55.12 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +39.5% |
|---|
Price levels it has turned at before
FBRX last closed at $76.92 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $35.71 | Support | 53.6% below the last close | turned there twice · 2026-01-27 to 2026-04-09 |
| $32.97 | Support | 57.1% below the last close | turned there twice · 2026-02-17 to 2026-03-05 |
| $26.67 | Support | 65.3% below the last close | turned there three times · 2026-01-30 to 2026-02-26 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Near the 52-week high · in a Bollinger Band volatility squeeze | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.60 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$73.80 range $61.00 – $77.00; median $77.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for FBRX
- Consensus EPS estimate-$0.781 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: FB102 is in Phase 1b/early Phase 2 trials; failure to demonstrate efficacy or safety in ongoing patient studies could halt development and eliminate the company's primary asset","Cash burn and funding risk: The company is unprofitable with negative revenue, cash declining from $77M to $58M in Q1 2026, and will require additional financing to continue development through late-stage trials","Competitive and regulatory risk: No approved treatments currently exist for celiac disease, but competition from established immunology players and regulatory approval pathways remain uncertain"]
What changed in the latest 10-Q
AI-assisted comparison of FBRX's 10-Q filed 2026-05-11 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number for Item 2 (MD&A) changed from 20 to 17
- Page number for Item 3 (Quantitative and Qualitative Disclosures About Market Risk) changed from 29 to 25
- Page number for Item 4 (Controls and Procedures) changed from 29 to 25
- Page number for PART II OTHER INFORMATION changed from 30 to 26
- Page number for Item 1 (Legal Proceedings) changed from 30 to 26
- Notes:
- These changes reflect only page numbering differences in the table of contents between the two filings; no substantive content changes are evident from the provided excerpts.
Risk Factors
- Added:
- Newer filing (2026-05-11) includes financial data for Q1 2026 (three months ended March 31, 2026) compared to older filing (2025-11-14) which reports Q3 2025 (three months and nine months ended September 30, 2025)
- Newer filing shows March 31, 2026 balance sheet with cash of $58,223 thousand; older filing shows September 30, 2025 balance sheet with cash of $93,414 thousand
- Newer filing reports accumulated deficit of $245,509 thousand as of March 31, 2026; older filing reports $198,585 thousand as of September 30, 2025
- Newer filing includes reference to April 8, 2026 closing of public offering of 5,709,936 shares at $26.27 per share in the Liquidity and Risks section
- Newer filing shows income tax expense of $373 thousand for three months ended March 31, 2026; older filing shows no income tax expense for comparable periods
- Newer filing includes 'Accretion of debt discount on available-for-sale securities' line showing $(7) thousand; older filing shows $(246) thousand for nine months and different methodology
- Removed:
- Older filing (2025-11-14) includes short-term investments of $36,121 thousand as of December 31, 2024; newer filing shows no short-term investments as of March 31, 2026
- Older filing shows 'Other liabilities' line item in balance sheet; newer filing includes this but with different amounts ($1,476 thousand vs $1,037 thousand)
- Older filing includes nine-month comparative periods for statements of operations and cash flows; newer filing shows only three-month periods
- Reworded:
- Newer filing uses 'Accretion of debt discount on available-for-sale securities' with negative values; older filing uses same terminology with different context of short-term investments
- Notes:
- The two filings report different fiscal periods (Q1 2026 vs Q3 2025), making direct operational comparisons limited
- Accumulated deficit increased by $46,924 thousand between September 30, 2025 and March 31, 2026, reflecting approximately 6 months of operations
- The newer filing is a Q1 10-Q while the older filing is a Q3 10-Q, representing different quarterly reporting periods in different fiscal years
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for FBRX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding FBRX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 694,806
- Reported value $17,995,476
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
FBRX had 1,904,726 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
FBRX had 13.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1 days to cover at the same settlement.
- Reported short interest (shares) 1,904,726
- Short interest (% of shares outstanding) 13.7%
- Prior settlement (shares) 2,060,636
- Reported change -7.57%
- Days to cover (reported) 1
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- AbbVie (ABBV)
- Eli Lilly (LLY)
- Regeneron Pharmaceuticals (REGN)
- Sanofi (SNY)
- Incyte (INCY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare FBRX vs…
FORTE BIOSCIENCES INC is found in…
FBRX ranks in…
Frequently asked questions
What does FORTE BIOSCIENCES INC (FBRX) do?
Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, a proprietary anti-CD122 monoclonal antibody intended to treat autoimmune and autoimmune-related disorders by antagonizing IL-2/IL-15 receptors that regulate NK cells and T cell subsets. The company is advancing FB102 through Phase 1b and Phase 2 trials in celiac disease, non-segmental vitiligo, and alopecia areata, with positive Phase 1b data in celiac disease showing significant reduction in intestinal…
What sector is FORTE BIOSCIENCES INC (FBRX) in?
FORTE BIOSCIENCES INC (FBRX) is classified in the Health Care sector. Its industry is Clinical-stage monoclonal antibody therapeutics for autoimmune diseases. It trades on NASDAQ.
Who are FORTE BIOSCIENCES INC's (FBRX) competitors?
Notable peers of FORTE BIOSCIENCES INC (FBRX) include Amgen, AbbVie, Eli Lilly, Regeneron Pharmaceuticals and Sanofi. This peer set is informational only — not financial advice.
Is FORTE BIOSCIENCES INC (FBRX) overbought or oversold right now?
FORTE BIOSCIENCES INC (FBRX) is currently in overbought territory (its 14-day RSI is 84, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on FBRX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.